Search company, investor...

GenFleet Therapeutics

Founded Year



Series C | Alive

Total Raised


Last Raised

$75M | 1 yr ago

About GenFleet Therapeutics

GenFleet Therapeutics is a clinical-stage biotechnology company focusing on therapies in oncology and immunology. Dedicated to serving significant unmet medical needs, GenFleet Therapeutics established its R&D platform based on the deep understanding of disease biology, translational medicine, as well as the research into latest biological mechanism of cancer pathways, tumor microenvironment and human immunoregulation.

Headquarters Location

1206 Zhangjiang Road Building A

Shanghai, Shanghai,


+86 021-6882 1388

Compete with GenFleet Therapeutics?

Ensure that your company and products are accurately represented on our platform.

GenFleet Therapeutics's Products & Differentiators


    Innovative small molecule for treatment of autoimmune diseases

Expert Collections containing GenFleet Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

GenFleet Therapeutics is included in 2 Expert Collections, including Biopharma Tech.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.



3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

GenFleet Therapeutics Patents

GenFleet Therapeutics has filed 9 patents.

The 3 most popular patent topics include:

  • Transcription factors
  • Proteins
  • Prodrugs
patents chart

Application Date

Grant Date


Related Topics




Transcription factors, Human proteins, Clusters of differentiation, Developmental genes and proteins, Proteins


Application Date


Grant Date



Related Topics

Transcription factors, Human proteins, Clusters of differentiation, Developmental genes and proteins, Proteins



Latest GenFleet Therapeutics News

GenFleet Therapeutics to Present Phase I Data for GFH312 at 2023 American Society for Clinical Pharmacology & Therapeutics Meeting

Mar 9, 2023

News provided by Share this article Share this article SHANGHAI, March 9, 2023 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced the results from phase I study of GFH312 (RIPK1 inhibitor) monotherapy will be presented as a poster at the 2023 ASCPT Meeting in Atlanta on March 22nd. GFH312 is safe and well tolerated in healthy subjects in single or multiple doses with favorable PK /PD profile to support further clinical development. As of July 2022, no grade 3 or above adverse effects were reported among all subjects. A rapid inhibition of RIPK1 phosphorylation in PBMCs was observed as soon as 2 hours post dosing in all dose groups and a sustained inhibition was achieved post multiple dosages. The data of cerebrospinal fluid (CSF) analysis from subjects receiving 120 mg daily administration suggest that GFH312 has exposure in the CNS and may potentially be useful for treating neurological indications. The phase I study of GFH312 was completed in Australia and GenFleet has been granted with the FDA approval for phase II study of GFH312. "GFH312 is GenFleet's first clinical-stage product granted with FDA's IND approval for phase II study in non-oncology indication. The phase I study of GFH312 exhibited excellent safety/tolerability and fast inhibition of RIPK1 phosphorylation at the cellular level in subjects. RIPK1 is an important regulator of multiple signaling pathways in inflammation and necropoptosis. We hope to further explore multiple indications including neurological and inflammatory diseases." said by Yu Wang, M.D.,Ph.D., Chief Medical Officer of GenFleet. A FIRST-IN-HUMAN PHASE I STUDY OF THE GFH312 A RIPK1 INHIBITOR, EVALUATING SAFETY/TOLERABILITY AND PHARMACOKINETICS IN HEALTHY SUBJECTS Code: EP-032 This is a randomized (3:1), double-blinded, placebo-controlled first-in-human (FIH) study to assess safety/tolerability, pharmacokinetics and pharmacodynamics of GFH312 in healthy subjects, including seven single ascending dose (SAD) and three multiple ascending dose (MAD) cohorts. As of June 8, 2022, a total of 76 subjects have been enrolled into above dose levels. No grade 3 or above AEs were reported. GFH312 was rapidly absorbed post a single oral dose with a median Tmax of 2 h ~ 8 h and eliminated with half-life of 6.3 ~ 23.3 h. Linear pharmacokinetic (PK) behavior was observed over the dose range from 45 mg to 360 mg. Limited accumulation was observed after multiple doses with accumulation ratio (RACmax and RAAUC) <2-fold across all dose cohorts GFH312 is safe and well tolerated in healthy subjects at either single or multiple doses, the PK characteristics support further clinical development of GFH312. About RPIK1 and GFH312 As a subtype of receptor interacting protein kinase family, RIPK1 is a central regulator of multiple immune signaling pathways. Widely expressed in human cells, the serine/threonine kinase of RIPK1 is most abundant in adipocytes, endothelial and perivascular cell clusters and also discovered in immune cell clusters (dendritic cells, macrophages and T cells). Small-molecule RIPK1 inhibitors are expected to show efficacy for treating neurological, inflammatory and autoimmune diseases (including psoriasis, rheumatoid arthritis, ulcerative colitis, etc.). In vitro experiments demonstrate that GFH312 blocks the process of TNF-α-induced necroptosis. It's observed in a variety of animal models that GFH312 can reduce inflammation and resist necroptosis; besides, low dosage of GFH312 can significantly improve the action capability of experimental animals and decrease the death risk caused by acute systemic inflammation. The phase I clinical trial data confirm the safety and tolerability of GFH312. About GenFleet Therapeutics GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies, is dedicated to serving significant global unmet medical needs in oncology and immunology. Based on the deep understanding of disease biology and translational medicine, GenFleet's proprietary and fully integrated R&D platform highlights multiple cutting-edge products with novel mechanisms and global IP. Since its inception in 2017, GenFleet has built up industry-leading capabilities and expertise in developing novel drug candidates - both small molecules and biologics. Its pipeline includes over 10 programs, many of which have entered multi-regional clinical trials across China (including Taiwan), the United States, Europe and Australia. To date, GenFleet has over 5 clinical studies encompassing IND stage to phase II studies and completed co-development partnerships with a number of publicly listed companies worldwide. GenFleet is expected to progress additional programs into the clinic, as well as transition from a clinical stage biotech company into a commercial stage biopharmaceutical company in the next 3-5 years. SOURCE GenFleet Therapeutics

GenFleet Therapeutics Frequently Asked Questions (FAQ)

  • When was GenFleet Therapeutics founded?

    GenFleet Therapeutics was founded in 2017.

  • Where is GenFleet Therapeutics's headquarters?

    GenFleet Therapeutics's headquarters is located at 1206 Zhangjiang Road, Shanghai.

  • What is GenFleet Therapeutics's latest funding round?

    GenFleet Therapeutics's latest funding round is Series C.

  • How much did GenFleet Therapeutics raise?

    GenFleet Therapeutics raised a total of $165.81M.

  • Who are the investors of GenFleet Therapeutics?

    Investors of GenFleet Therapeutics include CDH Investments, Fortune United Partners, Lake Bleu Capital, Shanjin Capital, ABC International and 24 more.

  • What products does GenFleet Therapeutics offer?

    GenFleet Therapeutics's products include GFH312.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.